Introduction {#j_jvetres-2017-0061_s_001}
============

From the perspective of the quality and hygiene standard of milk, veterinary medicines are classified among foreign substances and contaminants. The presence of their residues in raw milk, especially if they are present in concentrations exceeding the permitted limits, is an issue of concern for public health. To protect the health of consumers while ensuring quality of raw materials for the production of dairy products, it is necessary to monitor the presence of veterinary drug residues in raw milk ([@j_jvetres-2017-0061_ref_006]).

The monitoring system for veterinary medicine residues in animal products includes plate diffusion methods. They belong to the microbial inhibition methods and they are based on the reaction between a specific sensitive bacterial strain and an antimicrobial compound present in the sample examined ([@j_jvetres-2017-0061_ref_007]). The advantages of these methods include the capability to simultaneously detect a broad spectrum of antimicrobials with different chemical structures. These techniques allow identification of groups of antimicrobials and their semi-quantitative determination, thus they are used as screening as well as post-screening methods ([@j_jvetres-2017-0061_ref_006], ([@j_jvetres-2017-0061_ref_015]). Plate diffusion methods are being developed constantly. One of the main reasons for diversification is the ever-expanding range of veterinary medicinal products approved for the treatment of animals intended for food production ([@j_jvetres-2017-0061_ref_010]). The continuously adjusted requirements regarding analytical methods including those for antimicrobial detection in raw materials and foodstuffs of animal origin constitute another reason. Performance criteria and procedures for the validation of screening and confirmatory methods are established in the EU legislation ([@j_jvetres-2017-0061_ref_008]).

Numerous studies on the development and validation of new plate diffusion methods published in the last twenty years aimed at increasing the sensitivity of the methods to selected analytes, due to the establishment of permissible antimicrobial limits ([@j_jvetres-2017-0061_ref_015], ([@j_jvetres-2017-0061_ref_018], ([@j_jvetres-2017-0061_ref_021], ([@j_jvetres-2017-0061_ref_022]). Some of the studies are devoted to determining sensitivity of plate diffusion methods to a broad spectrum of antimicrobials. Other studies, however, focus on the development and validation of new methods aimed at detection of a specific group of antimicrobials. One of the antimicrobial groups which was the subject of interest of certain studies was quinolone chemotherapeutics.

Quinolone chemotherapeutics represent further progress in developing and expanding the spectrum of antimicrobials for effective treatment of infectious diseases in human medicine. Use of fluoroquinolones in veterinary medicine increased significantly at the end of the 20th century globally, including in the Czech Republic. Their application varies depending on the animal species, indication, region, and permitted MRLs. As indicated by statistical data, the most commonly used agents in the treatment of livestock in Europe include enrofloxacin, difloxacin, flumequine, marbofloxacin, danofloxacin, and oxolinic acid ([@j_jvetres-2017-0061_ref_002]).

To determine quinolone chemotherapeutic content, the plate diffusion method using an *E. coli* strain was added to the existing range of laboratory techniques, as recommended by Ellerbroek ([@j_jvetres-2017-0061_ref_011]). The *E. coli* method is contained in a number of multiplate methods ([@j_jvetres-2017-0061_ref_013], [@j_jvetres-2017-0061_ref_015], [@j_jvetres-2017-0061_ref_016], [@j_jvetres-2017-0061_ref_019]). Some studies, however, confirmed that this method has a lower sensitivity to flumequine and oxolinic acid, and thus other bacteria sensitive to quinolones were tried. Alternatives to *E. coli* used in foreign studies to detect quinolone chemotherapeutics included *Klebsiella pneumoniae* ATTC 10031 and *Yersinia ruckeri* NCIMB 13282 ([@j_jvetres-2017-0061_ref_023]). Nevertheless, most studies focused on increasing the sensitivity of plate methods to detect quinolone residues in muscles and organs, not in raw milk, although it is a strategic raw material for human nutrition, especially for children.

The aim of the study was to select a *Yersinia* spp. strain for the plate diffusion method based on sensitivity to flumequine, one of the fluoroquinolones. Another aim of the study was to set the optimum conditions of the plate method with the selected strain and to determine its sensitivity to selected fluoroquinolones. Fluoroquinolones used in veterinary medicine in cattle, *i.e*. danofloxacin, marbofloxacin, ciprofloxacin, enrofloxacin, and flumequine were selected for the study.

Material and Methods {#j_jvetres-2017-0061_s_002}
====================

Preparation of standard solutions {#j_jvetres-2017-0061_s_002_s_001}
---------------------------------

To prepare standard solutions of quinolone chemotherapeutics, the following analytical standards purchased from Sigma Aldrich (USA) were used: ciprofloxacin (17850, Fluka, Germany), enrofloxacin (17849, Fluka), flumequine (F 7016, Sigma Aldrich, USA), danofloxacin (3377, Riedel-deHaën, Germany), and marbofloxacin (34039, Riedel-deHaën). Standard solutions of fluoroquinolone chemotherapeutics with the active substance concentration of *c*= 1 mg/mL were prepared by initially dissolving a calculated weighed amount of the standard in 1 mL of 0.1 mol/L NaOH, and subsequently they were diluted to the desired volume with distilled water. Working solutions were prepared from standard solutions by further diluting with distilled water.

Tested strains {#j_jvetres-2017-0061_s_002_s_002}
--------------

Strains of *Yersinia* spp. were obtained from the Czech Collection of Microorganisms (Czech Republic). The following strains of *Yersinia* spp. were used for the study: *Y. aldovae* CCM 3754 ([@j_jvetres-2017-0061_ref_004]), *Y. ruckeri* CCM 4620 ([@j_jvetres-2017-0061_ref_012]), *Y. bercovieri* CCM 4207 ([@j_jvetres-2017-0061_ref_024]), *Y. mollaretii* CCM 4209 ([@j_jvetres-2017-0061_ref_024]), *Y. rohdei* CCM 4075 ([@j_jvetres-2017-0061_ref_001]), and *Y. ruckeri* (NCIMB 13 282) CCM 8467 ([@j_jvetres-2017-0061_ref_023]).

Sensitivity testing with strains of *Yersinia* spp. and optimisation of conditions {#j_jvetres-2017-0061_s_002_s_003}
----------------------------------------------------------------------------------

Gelatin carriers of selected strains of *Yersinia* spp. were revived according to the manufacturer's recommendations (Czech Collection of Microorganisms). The 24-hour-old cultures in slant TSA (TSA, M593, HiMedia, India) were used to prepare test strain suspensions of various densities. Suspension density (CFU/mL) was determined by comparison with the McFarland standard (0.5, 1, 2, 3, and 4.5) and then checked by densitometer. The suspension was inoculated onto the test agar at pH 6.0 (Antimicrobial Inhibitor Test Agar with a pH of 6.0; M1631, HiMedia) and its pH 8.0 counterpart (Antimicrobial Inhibitor Test Agar with a pH of 8.0; M1632 HiMedia) at 45--48°C. Portions of the agar (4 mL) were transferred into prewarmed sterile glass Petri dishes of 90 mm diameter. Sensitivity of the methods to ciprofloxacin was tested using 10 μL of working solution of ciprofloxacin (*c*= 0.3 μg/mL) in a disc with a diameter of 6 mm. Plates were incubated at the optimal strain growth temperature (according to the manufacturer's recommendations) for 18--24 h. Furthermore, the flumequine sensitivity of the plates with individual testing strains was tested with milk samples with known concentrations of flumequine (concentrations of 0.5, 1, 1.5, 2, 2.5, and 3 MRL) by applying a 100 μL sample to a 12.7 mm diameter disc.

Setting the optimum method conditions for the selected strain of *Y. ruckeri* CCM 8467 {#j_jvetres-2017-0061_s_002_s_004}
--------------------------------------------------------------------------------------

To adjust the method sensitivity, it was important to select the optimum agar pH, the concentration of strain cells in agar (test strain suspension density), and incubation temperature (30 or 37°C). The method was tested with agar with pH 6.0 and 8.0 and with various concentrations of strain cells (CFU/mL). Strain suspensions with various test strain concentrations were prepared using the McFarland scale (0.5, 1, 2, 3, and 4.5). Setting the optimum method conditions was performed by testing milk samples with flumequine concentrations at levels of 0.5--3 times the MRL and by a procedure equivalent to sensitivity testing using ciprofloxacin solution.

Preparation of plate method with the test strain of *Y. ruckeri* CCM 8467 {#j_jvetres-2017-0061_s_002_s_005}
-------------------------------------------------------------------------

The strain of *Y. ruckeri* CCM 8467 supplied as a gelatin disc was revived in accordance with the producer's recommendations (Czech Collection of Microorganisms). The 24-hour-old culture in slant TSA (TSA, M593, HiMedia, India) was used to prepare the test strain suspension. Suspension concentration (amount of CFU/mL) was determined by comparison with the McFarland scale (no. 3). The suspension was inoculated in the test agar specified to pH 6.0 (Antimicrobial Inhibitor Test Agar, M1631, HiMedia) at 45--48°C. Four millilitres of the agar was transferred into pre-warmed sterile glass Petri dishes of 90 mm diameter. Method sensitivity was tested using 10 μL of ciprofloxacin working solution (*c*= 0.3 μg/mL) in a 6-mm disc.

Preparation of fortified milk samples {#j_jvetres-2017-0061_s_002_s_006}
-------------------------------------

Sensitivity of the plate diffusion method with *Yersinia ruckeri* CCM 8467 to selected fluoroquinolones was tested using samples of milk fortified with fluoroquinolones. Fortified milk samples were prepared by diluting a calculated amount of the working solution of chemotherapeutics in milk. Fortified milk samples with fluoroquinolone concentrations of 0.5, 1, 2, 2.5, and 3 MRL were prepared from working solutions.

Determination of method sensitivity (detection capability) {#j_jvetres-2017-0061_s_002_s_007}
----------------------------------------------------------

Sensitivity determination of the plate method with *Y. ruckeri* to the selected fluoroquinolones was performed using discs with a diameter of 12.7 mm (Blank Paper Discs, Albet LabScience, Spain) and absorbency of 100 μL of milk sample. Each sample with the standard concentration of the antibiotic was tested 20 times. Plates were incubated at 30°C for at least 18 h. After the incubation was complete, the size of the inhibition zone was evaluated. The zone size was measured using a dedicated scale (Antibiotic Zonescale, HiMedia). A regular inhibition zone around the disc of ≥ 2 mm was interpreted as a positive (suspect) test result.

Results {#j_jvetres-2017-0061_s_003}
=======

Testing sensitivity of collection strains to ciprofloxacin and flumequine {#j_jvetres-2017-0061_s_003_s_001}
-------------------------------------------------------------------------

Selected collection strains of *Yersinia* spp., namely *Y. aldovae* CCM 3754 ([@j_jvetres-2017-0061_ref_004]), *Y. ruckeri* CCM 4620 ([@j_jvetres-2017-0061_ref_012]), *Y. bercovieri* CCM 4207 ([@j_jvetres-2017-0061_ref_024]), *Y. mollaretii* CCM 4209 ([@j_jvetres-2017-0061_ref_024]), *Y. rohdei* CCM 4075 ([@j_jvetres-2017-0061_ref_001]), and *Y. ruckeri* CCM 8467 ([@j_jvetres-2017-0061_ref_023]), were used as test strains in the plate diffusion method. Based on the strains' growth in agar media of different pH (pH 6.0 and 8.0), readability of the inhibition zones, and size of the inhibition zone around the disc with positive control, the optimal concentration of cells in the agar medium was set at about 9.10^5^--10^6^ CFU/mL and the agar pH level of 6.0 was chosen. The plates with agar medium of pH 6.0 prepared with collection strains were tested for sensitivity to the fluoroquinolones ciprofloxacin and flumequine. The sensitivity of the plate methods to ciprofloxacin was tested by application of 10 μL of ciprofloxacin working solution with concentration of 0.3 μg/mL, which was used as a positive control in a disc with a diameter of 6 mm. Except for those using *Y. mollaretii* and *Y. ruckeri* CCM 4620 test strains, all plate methods were sensitive to ciprofloxacin ([Table 1](#j_jvetres-2017-0061_tab_001){ref-type="table"}). The flumequine sensitivity of the plates with individual testing strains was tested with fortified milk samples with flumequine concentrations 0.5, 1, 1.5, 2, 2.5, and 3 MRL) by applying a 100 μL sample to a 12.7 mm diameter disc. Of the six strains tested, only the plate method with the *Y. ruckeri* strain CCM 8467 demonstrated sensitivity to flumequine in concentrations of 2, 2.5, and 3 times MRL.

###### 

Sensitivity of the plate methods with *Yersinia* spp

  Antimicrobial substance   *Y. aldovae* CCM 3754   *Y. bercovieri* CCM 4207   *Y. mollaretii* CCM 4209   *Y. rohdei* CCM 4075   *Y. ruckeri* CCM 4620   *Y. ruckeri* CCM 8467
  ------------------------- ----------------------- -------------------------- -------------------------- ---------------------- ----------------------- -----------------------
  ciprofloxacine            4 mm                    6 mm                       0 mm                       9 mm                   0 mm                    6.5 mm

Setting conditions with the *Y. ruckeri* CCM 8467 strain {#j_jvetres-2017-0061_s_003_s_002}
--------------------------------------------------------

When setting the method conditions, the *Y. ruckeri* CCM 8467 strain sensitivity to flumequine was tested in agar with pH 6.0 and 8.0. Fortified milk samples with flumequine concentrations ranging from 1 to 3 times the MRL were investigated in plates with varying test strain cell concentrations. The sensitivity of the plates was also determined by testing 10 μL of ciprofloxacin working solution (*c* = 0.3 μg/mL) in a disc with a diameter of 6 mm. Based on the strain growth in agar mediums of different pH values (pH 6.0 and 8.0), readability of the inhibition zones, and size of the inhibition zone around the disc with the positive control, the optimal concentration of cells in the agar medium was set at about 9.10^5^--10^6^ CFU/mL. The mean size of inhibition zone in agar of pH 6.0 for the disc with the positive control (ciprofloxacin) was 6.5 ±1.5 mm. The *Y. ruckeri* method in agar of pH 8.0 at flumequine concentration equal to 3 times the MRL did not have sufficient sensitivity, since the size of the inhibition zone was only 0.5 mm. With agar of pH 6.0, the sample was assessed as suspect (inhibition zone size ≥2 mm) with flumequine concentration of 2 MRL. The results shown in [Table 2](#j_jvetres-2017-0061_tab_002){ref-type="table"} indicate that the method was more sensitive to flumequine in agar of pH 6.0.

###### 

Setting plate method conditions with *Y. ruckeri* CCM 8467, agar pH 6.0 and 8.0, testing milk samples with flumequine concentrations of 0.5--3 times the MRL, size of the inhibition zone in mm

  Agar pH   Flumequine concentration (multiple MRL)/size of the inhibition zone in mm 1 MRL 2.5                                         
  --------- ------------------------------------------------------------------------------------- ------------ ------------ ----------- -------------
  6.0       0                                                                                     3.5 ± 0.9    3.5 ± 0.7    4.5 ± 0.6   4.5 ± 0.5 0
  8.0       0                                                                                     0.25 ± 0.2   0.25 ± 0.2   0.5 ± 0.3   0.5 ± 0.3

Detection capability {#j_jvetres-2017-0061_s_003_s_003}
--------------------

The plates' sensitivity was determined in accordance with the requirements of EC legislation ([@j_jvetres-2017-0061_ref_008]) on performance characteristics of screening methods based on detection capability (*CCβ*). *CCβ* is defined in a clause of the Annex to Commission Decision 2002/657/EC ([@j_jvetres-2017-0061_ref_008]). *CCβ* is the smallest content of the analyte that may be detected, identified and/or quantified in a sample with an error probability of β. In the case of analytes with an established MRL, *CCβ* is the concentration at which the method is able to detect the permitted limit concentrations with a statistical certainty of 1-β. *CCβ* is the concentration at which only ≤5% false compliant results remain. In this case, *CCβ* must be less than or equal to the MRL ([@j_jvetres-2017-0061_ref_009]). Fortified milk samples with a standard fluoroquinolone concentration were used to determine the detection capability. Each fortified sample with a different basic concentration of the antibiotic (0.5, 1, 2, 2.5, and 3 times the MRL) was tested 20 times. The fortified samples with further concentrations of antibiotics for more specific designation of the level of the detection capability were tested 60 times. Testing of the modified method took place in two independent laboratories.

Detection capability determination with the *Y. ruckeri* CCM 8467 strain to selected fluoroquinolones {#j_jvetres-2017-0061_s_003_s_004}
-----------------------------------------------------------------------------------------------------

Based on the above results, the plate diffusion method using the *Y. ruckeri* CCM 8467 strain was tested: the concentration of cells in the agar medium was at 9.10^5^--10^6^ CFU/mL, discs were 12.7 mm in diameter. Antimicrobial Inhibitor Test Agar had pH of 6.0, incubation time lasted 18--24 h, and incubation temperature was 30°C. The sensitivity of the method with regard to the determined MRLs for the selected fluoroquinolones is shown in [Table 3](#j_jvetres-2017-0061_tab_003){ref-type="table"}. The method is especially sensitive to ciprofloxacin and enrofloxacin. The determined *CCβ* for the specified fluoroquinolones was at concentrations of 10 and 20 µg/L (0.1 and 0.2 times the MRL). Among other fluoroquinolones, the method is also capable of reliably detecting marbofloxacin. *CCβ* is at concentrations lower than the MRL at 30 μg/L (0.4 MRL). In relation to the MRL, the method is less sensitive to danofloxacin, where the *CCβ* value reaches concentrations slightly higher than the stipulated MRL (42 μg/L, 1.4 MRL). The results in [Table 3](#j_jvetres-2017-0061_tab_003){ref-type="table"} also show that *CCβ* for flumequine is equal to twice the limit, at 100 μg/L (2 MRL).

###### 

Detection capability -- *CCβ* of plate diffusion method with *Y. ruckeri* CCM 8467 for selected fluoroquinolones

  Antimicrobial   MRL EU                                                        *CCβ*   CCβ/MRL
  --------------- ------------------------------------------------------------- ------- ------------
  danofloxacin    30                                                            42      CCP \> MRL
  marbofloxacin   75                                                            30      CCP \< MRL
  flumequine      50                                                            100     CCP \> MRL
  enrofloxacin                                                                  20      CCP \< MRL
  ciprofloxacin   100[\*\*](#j_jvetres-2017-0061_fn_004){ref-type="table-fn"}   10      CCP \< MRL

sum of enrofloxacin and ciprofloxacin

Discussion {#j_jvetres-2017-0061_s_004}
==========

Antimicrobial residue examination in animal origin raw materials currently relies on a two-stage testing system based on current EU legislation ([@j_jvetres-2017-0061_ref_008]) which defines screening and confirmatory methods. A plate diffusion method is an integral part of the system of antimicrobial residue detection in milk in many countries and it is used mainly as a screening method. The commonly used plate diffusion methods include the Four-Plate Test (FPT) developed in 1980 by Bogaerts and Wolf ([@j_jvetres-2017-0061_ref_005]), which is, however, gradually being complemented and replaced by newly developed methods that show higher sensitivity to specific antimicrobial groups. In Europe, the Community Reference Laboratory in Fougères recommends 5-plate diffusion called the STAR method which involves a plate method with *E. coli* ATCC 11303 showing increased sensitivity to fluoroquinolones for the screening of antimicrobial residues in milk ([@j_jvetres-2017-0061_ref_014], ([@j_jvetres-2017-0061_ref_015]).

Navrátilová *et al*. ([@j_jvetres-2017-0061_ref_017]) confirmed, in consensus with other published data, that the plate method with *E. coli* ATCC 11303 is not sensitive enough to flumequine; its sensitivity to this antimicrobial being insufficient even at concentrations equal to 9 times the MRL. For the other tested fluoroquinolones (danofloxacin, marbofloxacin, ciprofloxacin, and enrofloxacin), the plate method with *E. coli* achieves detection capability *CCβ* in concentrations than the MRLs. In the past 20 years, plate methods applying bacteria other than *E. coli* to detect quinolones have been developed, but they have mostly focused on detecting quinolones in other products of animal origin (egg, meat, fish, and organs). The aim of this study was thus the selection of a test strain for a plate diffusion method which would exhibit sensitivity to fluoroquinolones, in particular to flumequine. As reported previously, one of the test strains suitable for quinolone detection is the *Y. ruckeri* strain. The *Y. ruckeri* plate method was developed to detect oxolinic acid in fish muscle ([@j_jvetres-2017-0061_ref_003]), later applied to detect other quinolones in eggs and poultry muscle ([@j_jvetres-2017-0061_ref_021]), or in meat and organs of slaughter animals ([@j_jvetres-2017-0061_ref_022]), but not in milk.

Of the collection strains of *Yersinia* spp. used to prepare the plate method and tested for sensitivity to ciprofloxacin and flumequine, only one strain, namely *Y. ruckeri* CCM 8467, demonstrated sensitivity to flumequine. Therefore it was selected as a test strain for the plate diffusion method. The sensitivity of a plate method can be influenced by a variety of factors: composition and pH of the agar medium, selection of the test strain, test cell concentration in the agar medium, sample application method, sample quantity, pH of the sample to be examined, incubation period, and temperature. The selected optimum concentration of test strain cells in the agar medium was close to the cell concentration of 10^6^ CFU/mL which was selected by Pikkemaat *et al*. ([@j_jvetres-2017-0061_ref_022]) in the plate method with *Y. ruckeri* NCIM 13282 to detect quinolones in muscles and organs. Based on the examination results of the milk samples enriched with flumequine, the test agar with pH 6.0 was selected, which corresponds to the results of a study by Okerman *et al*. ([@j_jvetres-2017-0061_ref_020]). In their view, flumequine detection appears optimal at agar pH 6.0, not at pH 8.0.

When examining samples of milk by a plate diffusion method, paper discs of a specific size with standard absorbency are usually used. Alternatively, the application of milk samples may be performed directly into the wells formed in the agar. The method sensitivity was increased by applying a milk sample to a 12.7 mm disc having the ability to absorb a sample volume of 100 μL. For example, the STAR method recommends 9 mm discs that have absorption capacity of 30 μL to examine milk. The *Y. ruckeri* strain showed better growth ability at 30°C, which is consistent with other studies using the *Y. ruckeri* strain as a test strain in a plate diffusion method ([@j_jvetres-2017-0061_ref_021], ([@j_jvetres-2017-0061_ref_022]).

The method with *Y. ruckeri* CCM 8467 test strain seems among fluoroquinolones to be very sensitive to ciprofloxacin and enrofloxacin. The sensitivity was comparable with the plate method using *E. coli* ([@j_jvetres-2017-0061_ref_017]), in which the value of *CCβ* reached 40 µg/L for enrofloxacin and 20 µg/L for ciprofloxacin, thus lower than 0.5 of MRL ([@j_jvetres-2017-0061_ref_017]). The method is also well able to detect marbofloxacin; *CCβ* is at concentrations of 30 µg/L. In the *E. coli* method, the sensitivity reaches levels slightly lower than the set limit (70 µg/L x 75 µg/kg). The results also show that *CCβ* for flumequine achieves 100 µg/L (twice the MRL). When compared to the sensitivity of the plate method with *E. coli* which did not show sensitivity even at a concentration of flumequine equal to nine times the MRL, the *Y. ruckeri* method is more sensitive, nevertheless, it is not sensitive enough to meet the requirement for screening methods that should be sensitive to amounts equal to or less than the MRL.

In conclusion, it can be summarised that by determining the detection capability of the plate diffusion method with the *Yersinia ruckeri* CCM 8467 strain for selected fluoroquinolones, it was found that this method is able to reliably detect the fluoroquinolones ciprofloxacin, enrofloxacin, and marbofloxacin. With regard to the MRL, the method is less sensitive to danofloxacin and flumequine. In the system of antimicrobial substance detection, it is important that the screening method sensitivity to antimicrobial agents is determined at concentrations close to the respective MRL or lower. The plate method with *Yersinia ruckeri* CCM 8467 provides a sensitivity improvement over the Community Reference Laboratory's recommended method for flumequine screening but does not meet the requirement for screening methods that should be sensitive to amounts equal to or less than the MRL. Further work is necessary to hone the method's sensitivity.
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